Q Biomed Inc. Closes $5.48 Million Public Offering

Company Expects Commercialization and Revenue from its Non-Opioid Pain Palliation Drug in Q2 2018 and Initiation of Multiple Pivotal Clinical Programs in 2018 NEW YORK, February 1, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology...

Q BioMed Inc. Prices $5.5 Million Public Offering

Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018 NEW YORK, January 30, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO) (“Q BioMed” or the “Company”), a commercial stage biotechnology...

Q Biomed Inc. to Present at Biotech Showcase(™) 2018

NEW YORK, January 3, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin, Chief Executive Officer, will present at the Biotech Showcase(™) 2018 Conference to be held January 8 – 10,...

Q BioMed Provides Year End Update

Company Ends Year with an Advancing Full Pipeline and a Catalyst Rich Year Ahead NEW YORK, Dec. 21, 2017 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to provide this year end update to its shareholders....